University of Wisconsin Foundation Increases Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Key Points

• The University of Wisconsin Foundation increased its holdings in Madrigal Pharmaceuticals by 16.5%, making it the foundation's third largest position, representing 12.4% of its total portfolio.
• Madrigal Pharmaceuticals reported an EPS of ($1.90) for the last quarter, outperforming analysts' expectations and showing significant year-over-year revenue growth of 1357.5%.
• Several equity analysts have issued "buy" ratings for Madrigal Pharmaceuticals, with price targets reflecting expectations of significant price appreciation, the highest being up to $523.00.

University of Wisconsin Foundation increased its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 16.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,376 shares of the biopharmaceutical company's stock after acquiring an additional 6,835 shares during the period. Madrigal Pharmaceuticals makes up about 12.4% of University of Wisconsin Foundation's holdings, making the stock its 3rd biggest position. University of Wisconsin Foundation owned 0.22% of Madrigal Pharmaceuticals worth $16,024,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Candriam S.C.A. bought a new stake in Madrigal Pharmaceuticals during the 1st quarter worth approximately $7,079,000. Groupama Asset Managment increased its holdings in Madrigal Pharmaceuticals by 37.5% during the 1st quarter. Groupama Asset Managment now owns 33,452 shares of the biopharmaceutical company's stock worth $10,968,000 after acquiring an additional 9,128 shares during the period. Summit Securities Group LLC bought a new stake in Madrigal Pharmaceuticals during the 1st quarter worth approximately $33,000. American Century Companies Inc. increased its holdings in Madrigal Pharmaceuticals by 15.7% during the 1st quarter. American Century Companies Inc. now owns 158,306 shares of the biopharmaceutical company's stock worth $52,436,000 after acquiring an additional 21,457 shares during the period. Finally, Sei Investments Co. increased its holdings in Madrigal Pharmaceuticals by 22.8% during the 1st quarter. Sei Investments Co. now owns 10,104 shares of the biopharmaceutical company's stock worth $3,162,000 after acquiring an additional 1,875 shares during the period. Institutional investors own 98.50% of the company's stock.

Analyst Ratings Changes

MDGL has been the topic of a number of analyst reports. JMP Securities upped their target price on shares of Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 20th. Canaccord Genuity Group increased their price target on shares of Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Cowen reissued a "buy" rating on shares of Madrigal Pharmaceuticals in a report on Tuesday. UBS Group reissued a "buy" rating and issued a $523.00 price target (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 12th. Finally, B. Riley reissued a "buy" rating and issued a $460.00 price target (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday, May 2nd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $459.25.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 1,304 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $367.81, for a total transaction of $479,624.24. Following the completion of the sale, the general counsel owned 9,173 shares of the company's stock, valued at $3,373,921.13. This represents a 12.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO William John Sibold sold 7,616 shares of the firm's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $400.18, for a total transaction of $3,047,770.88. Following the completion of the sale, the chief executive officer directly owned 109,753 shares in the company, valued at approximately $43,920,955.54. This trade represents a 6.49% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 165,683 shares of company stock worth $61,921,142 and have sold 301,740 shares worth $109,461,331. Company insiders own 21.50% of the company's stock.

Madrigal Pharmaceuticals Trading Down 1.1%

Shares of Madrigal Pharmaceuticals stock traded down $4.61 during trading on Friday, reaching $432.56. The company's stock had a trading volume of 99,931 shares, compared to its average volume of 379,965. Madrigal Pharmaceuticals, Inc. has a 52-week low of $200.63 and a 52-week high of $439.00. The company has a market cap of $9.60 billion, a price-to-earnings ratio of -33.61 and a beta of -1.02. The firm's 50-day moving average is $332.43 and its two-hundred day moving average is $319.22. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.48) by $1.58. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The company had revenue of $212.80 million during the quarter, compared to analysts' expectations of $158.94 million. During the same quarter in the prior year, the company earned ($7.10) EPS. The firm's revenue was up 1357.5% on a year-over-year basis. On average, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.